{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:35:17Z","timestamp":1790094917164,"version":"4.0.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Treatment for moderate-to-severe acne vulgaris relies on prolonged use of oral tetracycline-class antibiotics; however, these broad-spectrum antibiotics are often associated with off-target effects and negative gastrointestinal sequelae. Sarecycline is a narrow-spectrum antibiotic treatment option. Here, we investigated the effect of prolonged sarecycline exposure, compared with broad-spectrum tetracyclines (doxycycline and minocycline) upon the colonic microbiota. Three <jats:italic>in vitro<\/jats:italic> models of the human colon were instilled with either minocycline, doxycycline or sarecycline, and we measured microbiota abundance and diversity changes during and after antibiotic exposure. Significant reductions in microbial diversity were observed following minocycline and doxycycline exposure, which failed to recover post antibiotic withdrawal. Specifically, minocycline caused a ~10% decline in Lactobacillaceae and Bifidobacteriaceae abundances, while doxycycline caused a ~7% decline in Lactobacillaceae and Bacteroidaceae abundances. Both minocycline and doxycycline were associated with a large expansion (&amp;gt;10%) of Enterobacteriaceae. Sarecycline caused a slight decline in bacterial diversity at the start of treatment, but abundances of most families remained stable during treatment. Ruminococcaceae and Desulfovibrionaceae decreased 9% and 4%, respectively, and a transient increased in Enterobacteriaceae abundance was observed during sarecycline administration. All populations recovered to pre-antibiotic levels after sarecycline exposure. Overall, sarecycline had minimal and transient impact on the gut microbiota composition and diversity, when compared to minocycline and doxycycline.<\/jats:p>","DOI":"10.3389\/fmicb.2022.901911","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T07:40:02Z","timestamp":1653982802000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Profiling the Effects of Systemic Antibiotics for Acne, Including the Narrow-Spectrum Antibiotic Sarecycline, on the Human Gut Microbiota"],"prefix":"10.3389","volume":"13","author":[{"given":"Ines B.","family":"Moura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Grada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Spittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Ewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Altringham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Fumero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1128\/AAC.02437-14","article-title":"Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment","volume":"58","author":"Angelakis","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref2","first-page":"s6","article-title":"Oral Tetracyclines and acne: A systematic review for dermatologists","volume":"19","author":"Armstrong","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref3","first-page":"26","article-title":"Oral antibiotic treatment options for acne vulgaris","volume":"13","author":"Baldwin","year":"2020","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1142.e1","DOI":"10.1016\/j.jaad.2016.06.057","article-title":"Duration of oral tetracycline-class antibiotic therapy and use of topical retinoids for the treatment of acne among general practitioners (GP): a retrospective cohort study","volume":"75","author":"Barbieri","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"456.e4","DOI":"10.1016\/j.jaad.2017.04.016","article-title":"Trends in prescribing behavior of systemic agents used in the treatment of acne among dermatologists and nondermatologists: a retrospective analysis, 2004\u20132013","volume":"77","author":"Barbieri","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/jac\/dkaa386","article-title":"Eravacycline, a novel tetracycline derivative, does not induce Clostridioides difficile infection in an in vitro human gut model","volume":"76","author":"Buckley","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"670935","DOI":"10.3389\/fcimb.2021.670935","article-title":"Trehalose-induced remodelling of the human microbiota affects Clostridioides difficile infection outcome in an in vitro colonic model: a pilot study","volume":"11","author":"Buckley","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1093\/jac\/dkv156","article-title":"Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model","volume":"70","author":"Chilton","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40265-019-1053-4","article-title":"Sarecycline: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1097\/MIB.0000000000000750","article-title":"Current understanding of dysbiosis in disease in human and animal models","volume":"22","author":"DeGruttola","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1371\/journal.pbio.0060280","article-title":"The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing","volume":"6","author":"Dethlefsen","year":"2008","journal-title":"PLoS Biol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1073\/pnas.1000087107","article-title":"Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation","volume":"108","author":"Dethlefsen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e035677","DOI":"10.1136\/bmjopen-2019-035677","article-title":"Antibiotic-induced changes in the human gut microbiota for the most commonly prescribed antibiotics in primary care in the UK: a systematic review","volume":"10","author":"Elvers","year":"2020","journal-title":"BMJ Open"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.3389\/fmicb.2015.01543","article-title":"Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances","volume":"6","author":"Francino","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/jac\/dkg267","article-title":"Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut","volume":"52","author":"Freeman","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/der2.49","article-title":"Treating acne with the tetracycline class of antibiotics: a review","volume":"2","author":"Graber","year":"2021","journal-title":"Dermatol. Rev."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/gut.2010.219683","article-title":"Antibiotic use and inflammatory bowel diseases in childhood","volume":"60","author":"Hviid","year":"2011","journal-title":"Gut"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1001\/jamadermatol.2016.5538","article-title":"Global skin disease morbidity and mortality: an update from the global burden of disease study 2013","volume":"153","author":"Karimkhani","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamadermatol.2020.1573","article-title":"The burden of skin and subcutaneous diseases in the United States from 1990 to 2017","volume":"156","author":"Laughter","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/cpt1973145852","article-title":"Pharmacokinetic studies on minocycline in man","volume":"14","author":"Macdonald","year":"1973","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s002489900072","article-title":"Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon","volume":"35","author":"Macfarlane","year":"1998","journal-title":"Microb. Ecol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1365-2672.2008.03792.x","article-title":"Influence of oral doxycycline therapy on the diversity and antibiotic susceptibility of human intestinal bifidobacterial population","volume":"105","author":"M\u00e4tt\u00f6","year":"2008","journal-title":"J. Appl. Microbiol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2217\/fmb-2019-0199","article-title":"Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris","volume":"14","author":"Moore","year":"2019","journal-title":"Future Microbiol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e01581","DOI":"10.1128\/AAC.01581-18","article-title":"Omadacycline gut microbiome exposure does not induce Clostridium difficile proliferation or toxin production in a model that simulates the proximal, medial, and distal human colon","volume":"63","author":"Moura","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12328-017-0813-5","article-title":"Gut microbiota in the pathogenesis of inflammatory bowel disease","volume":"11","author":"Nishida","year":"2018","journal-title":"Clin. J. Gastroenterol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/jac\/18.Supplement_C.159","article-title":"Impact of orally administered antimicrobial agents on human oropharyngeal and colonic microflora","volume":"18","author":"Nord","year":"1986","journal-title":"J. Antimicrob. Chemother."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41522-021-00184-w","article-title":"Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection","volume":"7","author":"Normington","year":"2021","journal-title":"NPJ Biofilms Microbiomes"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"578903","DOI":"10.3389\/fmicb.2020.578903","article-title":"A novel, orally delivered antibody therapy and its potential to prevent Clostridioides difficile infection in pre-clinical models","volume":"11","author":"Roberts","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/00000441-196805000-00005","article-title":"Absorption and excretion of five tetracycline analogues in normal young men","volume":"255","author":"Steigbigel","year":"1968","journal-title":"Am J Med Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5021\/ad.2020.32.1.21","article-title":"Minocycline and its impact on microbial dysbiosis in the skin and gastrointestinal tract of acne patients","volume":"32","author":"Thompson","year":"2020","journal-title":"Ann. Dermatol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e01297","DOI":"10.1128\/AAC.01297-18","article-title":"Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris","volume":"63","author":"Zhanel","year":"2018","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.901911\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T07:40:05Z","timestamp":1653982805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.901911\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":33,"alternative-id":["10.3389\/fmicb.2022.901911"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.901911","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"article-number":"901911"}}